NewLink Genetics Corp (NLNK) was Reiterated by Stifel to “Buy” while Lowering the Price Target of the company shares to $ 23 from a previous price target of $63 . Stifel advised their investors in a research report released on May 10, 2016.
Many Wall Street Analysts have commented on NewLink Genetics Corp. Robert W. Baird Initiated NewLink Genetics Corp on Mar 23, 2016 to “Outperform”, Price Target of the shares are set at $27.Shares were Reiterated by Mizuho on Mar 1, 2016 to “Buy” and Lowered the Price Target to $ 52 from a previous price target of $62 .
NewLink Genetics Corp closed down -0.2 points or -1.27% at $15.55 with 4,53,042 shares getting traded on Friday. Post opening the session at $15.75, the shares hit an intraday low of $15.15 and an intraday high of $16.07 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Apr 11, 2016, Charles J. Jr. Link (Chairman of the Board and CEO) sold 10,000 shares at $20.02 per share price. According to the SEC, on Jan 6, 2016, Brian Wiley (VP of Business Development) sold 1,295 shares at $34.73 per share price. On Jan 6, 2016, John B Iii Henneman (EVP, Chief Financial Officer) sold 175 shares at $35.74 per share price, according to the Form-4 filing with the securities and exchange commission.
NewLink Genetics Corporation (NewLink) is a biopharmaceutical company focused on discovering developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio includes both biologic and small-molecule immunotherapy product candidates. Its biologic product candidates are based on its HyperAcute immunotherapy technology which is designed to stimulate the human immune system. Its small-molecule product candidates are focused on breaking the immune system’s tolerance to cancer by inhibiting the indoleamine-(2 3)-dioxygenase (IDO) pathway. Its lead product candidate algenpantucel-L or HyperAcute Pancreas. HyperAcute Pancreas is being studied in two Phase III clinical trials; one in surgically-resected pancreatic cancer patients that is being performed under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA) and one in patients with locally advanced pancreatic cancer.